<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39460340</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>28</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2076-393X</ISSN><JournalIssue CitedMedium="Print"><Volume>12</Volume><Issue>10</Issue><PubDate><Year>2024</Year><Month>Oct</Month><Day>17</Day></PubDate></JournalIssue><Title>Vaccines</Title><ISOAbbreviation>Vaccines (Basel)</ISOAbbreviation></Journal><ArticleTitle>Comment on Fust et al. The Potential Economic Impact of the Updated COVID-19 mRNA Fall 2023 Vaccines in Japan. <i>Vaccines</i> 2024, <i>12</i>, 434.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">1174</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/vaccines12101174</ELocationID><Abstract><AbstractText>We noted three key inconsistencies in the Moderna-funded cost-effectiveness analysis by Fust et al [...].</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Volkman</LastName><ForeName>Hannah R</ForeName><Initials>HR</Initials><Identifier Source="ORCID">0000-0001-7274-9641</Identifier><AffiliationInfo><Affiliation>Pfizer Inc., New York, NY 10001, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nguyen</LastName><ForeName>Jennifer L</ForeName><Initials>JL</Initials><AffiliationInfo><Affiliation>Pfizer Inc., New York, NY 10001, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mustapha</LastName><ForeName>Mustapha M</ForeName><Initials>MM</Initials><AffiliationInfo><Affiliation>Pfizer Inc., New York, NY 10001, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jodar</LastName><ForeName>Luis</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Pfizer Inc., New York, NY 10001, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McLaughlin</LastName><ForeName>John M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Pfizer Inc., New York, NY 10001, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>n/a</GrantID><Agency>Pfizer (United States)</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Vaccines (Basel)</MedlineTA><NlmUniqueID>101629355</NlmUniqueID><ISSNLinking>2076-393X</ISSNLinking></MedlineJournalInfo><CommentsCorrectionsList><CommentsCorrections RefType="CommentOn"><RefSource>Vaccines (Basel). 12:434.</RefSource></CommentsCorrections></CommentsCorrectionsList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Japan</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">coronavirus</Keyword><Keyword MajorTopicYN="N">cost-effectiveness</Keyword><Keyword MajorTopicYN="N">vaccination</Keyword></KeywordList><CoiStatement>Hannah R. Volkman, Jennifer L. Nguyen, Mustapha M. Mustapha, Luis Jodar, and John M. McLaughlin declare employment and/or holding stocks and/or options at Pfizer Inc. during the conduct of the study. The authors declare no non-financial competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>5</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>10</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>10</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>26</Day><Hour>19</Hour><Minute>26</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>26</Day><Hour>19</Hour><Minute>25</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>26</Day><Hour>1</Hour><Minute>25</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>17</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39460340</ArticleId><ArticleId IdType="pmc">PMC11512365</ArticleId><ArticleId IdType="doi">10.3390/vaccines12101174</ArticleId><ArticleId IdType="pii">vaccines12101174</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Fust K., Joshi K., Beck E., Maschio M., Kohli M., Lee A., Hagiwara Y., Van de Velde N., Igarashi A. The Potential Economic Impact of the Updated COVID-19 mRNA Fall 2023 Vaccines in Japan. Vaccines. 2024;12:434. doi: 10.3390/vaccines12040434.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines12040434</ArticleId><ArticleId IdType="pmc">PMC11054439</ArticleId><ArticleId IdType="pubmed">38675816</ArticleId></ArticleIdList></Reference><Reference><Citation>Polack F.P., Thomas S.J., Kitchin N., Absalon J., Gurtman A., Lockhart S., Perez J.L., Pérez Marc G., Moreira E.D., Zerbini C., et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N. Engl. J. Med. 2020;383:2603–2615. doi: 10.1056/NEJMoa2034577.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2034577</ArticleId><ArticleId IdType="pmc">PMC7745181</ArticleId><ArticleId IdType="pubmed">33301246</ArticleId></ArticleIdList></Reference><Reference><Citation>Baden L.R., El Sahly H.M., Essink B., Kotloff K., Frey S., Novak R., Diemert D., Spector S.A., Rouphael N., Creech C.B., et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N. Engl. J. Med. 2021;384:403–416. doi: 10.1056/NEJMoa2035389.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2035389</ArticleId><ArticleId IdType="pmc">PMC7787219</ArticleId><ArticleId IdType="pubmed">33378609</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu B., Stepien S., Qian J., Gidding H., Nicolopoulos K., Amin J., Cheng A., Macartney K. Comparative effectiveness of four COVID-19 vaccines, BNT162b2 mRNA, mRNA-1273, ChAdOx1 nCov-19 and NVX-CoV2373 against SARS-CoV-2 B.1.1.529 (Omicron) infection. Vaccine. 2023;41:5587–5591. doi: 10.1016/j.vaccine.2023.07.050.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2023.07.050</ArticleId><ArticleId IdType="pubmed">37524631</ArticleId></ArticleIdList></Reference><Reference><Citation>Gálvez J.M., Pinzón-Rondón Á.M., Chaparro-Solano H.M., Tovar-Romero H.V., Ramírez-Prieto J., Ortigoza-Espitia S.A., Ruiz-Sternberg Á.M. Effectiveness of the Booster Dose in Protecting against COVID-19, Colombia 2022. Vaccines. 2023;11:1461. doi: 10.3390/vaccines11091461.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines11091461</ArticleId><ArticleId IdType="pmc">PMC10538081</ArticleId><ArticleId IdType="pubmed">37766137</ArticleId></ArticleIdList></Reference><Reference><Citation>Chin E.T., Leidner D., Lamson L., Lucas K., Studdert D.M., Goldhaber-Fiebert J.D., Andrews J.R., Salomon J.A. Protection against Omicron from Vaccination and Previous Infection in a Prison System. N. Engl. J. Med. 2022;387:1770–1782. doi: 10.1056/NEJMoa2207082.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2207082</ArticleId><ArticleId IdType="pmc">PMC9634863</ArticleId><ArticleId IdType="pubmed">36286260</ArticleId></ArticleIdList></Reference><Reference><Citation>Kirk B., Bush C., Toyip A., Mues K.E., Beck E., Li L., St. Laurent S., Georgieva M., Marks M.A., Sun T., et al. Real-world comparative effectiveness of a third dose of mRNA-1273 versus BNT162b2 among adults aged ≥65 years in the United States. medRxiv (Pre-Print) 2023 doi: 10.1101/2023.11.03.23298054.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2023.11.03.23298054</ArticleId><ArticleId IdType="pubmed">39030080</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee A., Davido B., Beck E., Demont C., Joshi K., Kohli M., Maschio M., Uhart M., El Mouaddin N. Substantial reduction in the clinical and economic burden of disease following variant-adapted mRNA COVID-19 vaccines in immunocompromised patients in France. medRxiv (Pre-Print) 2024 doi: 10.1101/2024.03.13.24304170.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2024.03.13.24304170</ArticleId></ArticleIdList></Reference><Reference><Citation>Joshi K., Scholz S., Maschio M., Kohli M., Lee A., Fust K., Ultsch B., Van de Velde N., Beck E. Clinical impact and cost-effectiveness of the updated COVID-19 mRNA Autumn 2023 vaccines in Germany. J. Med. Econ. 2024;27:39–50. doi: 10.1080/13696998.2023.2290388.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/13696998.2023.2290388</ArticleId><ArticleId IdType="pubmed">38050685</ArticleId></ArticleIdList></Reference><Reference><Citation>Kohli M.A., Maschio M., Joshi K., Lee A., Fust K., Beck E., Van de Velde N., Weinstein M.C. The potential clinical impact and cost-effectiveness of the updated COVID-19 mRNA fall 2023 vaccines in the United States. J. Med. Econ. 2023;26:1532–1545. doi: 10.1080/13696998.2023.2281083.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/13696998.2023.2281083</ArticleId><ArticleId IdType="pubmed">37961887</ArticleId></ArticleIdList></Reference><Reference><Citation>Centers for Disease Control and Prevention  COVID-19 Vaccine Uptake and CDC’s Commitment to Vaccine Equity 2023.  [(accessed on 15 May 2024)]; Available online:  https://www.cdc.gov/ncird/whats-new/vaccine-equity.html.</Citation></Reference><Reference><Citation>Centers for Disease Control and Prevention  Updated 2023–24 COVID-19 Vaccination Coverage, Adults 65 Years and Older, United States 2024.  [(accessed on 15 May 2024)]; Available online:  https://www.cdc.gov/covidvaxview/weekly-dashboard/adults-65yrs-older-vaccination.html?CDC_AAref_Val=https://www.cdc.gov/vaccines/imz-managers/coverage/covidvaxview/interactive/adults-65yrs-over-coverage.html.</Citation></Reference><Reference><Citation>European Centre for Disease Prevention and Control  COVID-19 Vaccine Tracker 2023.  [(accessed on 15 May 2024)].  Available online:  https://vaccinetracker.ecdc.europa.eu/public/extensions/COVID-19/vaccine-tracker.html#uptake-tab.</Citation></Reference><Reference><Citation>Prime Minister’s Office of Japan  COVID-19 Vaccines—Total Number of Vaccines Since Autumn 2023 2024.  [(accessed on 15 May 2024)].  Available online:  https://japan.kantei.go.jp/ongoingtopics/vaccine.html.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle>